Micropulse transscleral cyclophotocoagulation reduces IOP in minorities with glaucoma

Micropulse transscleral cyclophotocoagulation (MTS-CPC) was found to be effective at reducing intraocular pressure (IOP) and medication burden in African American adults with glaucoma, according to a poster presented at AAO 2022.

According to the presenters, there have been limited studies on the efficacy of MTS-CPC on minorities and underrepresented races.

In this single-surgeon, retrospective cohort study, 85 eyes of 80 African American adult patients with primary open angle glaucoma were treated with a single MTS-CPC with a minimum follow-up of 12 months, with data collected at 1 week, 1 month, 6 months, and 12 months.

Surgical success was defined as IOP of 6-21 mmHg or 20% reduction from baseline.

At 12 months, there was a significant reduction from preoperative IOP (24.1 ± 8.4 mmHg to 15.8 ± 7.3) and a reduction in the mean number of topical IOP-lowering medications (3.2 ± 1.3 to 2.6 ± 1.0)

The success rate at 12 months was 87.8%.

Reference
Dickinson AM, et al. Treatment Outcomes of Micropulse Transscleral Cyclophotocoagulation in African American Adults With Glaucoma. Poster presented at: AAO 2022.